Which has preferable valuation and earnings, BTMD or XGN?

biote has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.30 $27.05M $0.11 14.82 Exagen $66.57M 2.74 -$19.95M -$0.81 N/A

Is BTMD or XGN more profitable?

biote has a net margin of 3.19% compared to Exagen's net margin of -26.61%. biote's return on equity of -22.33% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets biote 3.19% -22.33% 12.10% Exagen -26.61% -104.46% -28.93%

Which has stronger valuation & earnings, LFMD or BTMD?

biote has lower revenue, but higher earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.81 $14.35M -$0.05 N/A biote $192.22M 0.30 $27.05M $0.11 14.82

Is LFMD or BTMD more profitable?

biote has a net margin of 3.19% compared to LifeMD's net margin of 0.10%. biote's return on equity of -22.33% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% biote 3.19% -22.33% 12.10%

Do analysts prefer JYNT or BTMD?

biote has a consensus price target of $2.50, suggesting a potential upside of 53.37%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, JYNT or BTMD?

biote has higher revenue and earnings than Joint. biote is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.17 $2.91M $0.27 31.15 biote $192.22M 0.30 $27.05M $0.11 14.82

Is JYNT or BTMD more profitable?

Joint has a net margin of 6.49% compared to biote's net margin of 3.19%. Joint's return on equity of 12.02% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% biote 3.19% -22.33% 12.10%

Is ACH or BTMD more profitable?

biote has a net margin of 3.19% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets Accendra Health -11.41% -4.02% 0.70% biote 3.19% -22.33% 12.10%

biote (BTMD) Competitors

$1.63 +0.08 (+5.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 -0.03 (-1.84%)

As of 07:30 PM Eastern

Compare

BTMD vs. XGN, LFMD, JYNT, PARK, and ACH

Should you buy biote stock or one of its competitors? biote's main competitors and comparable companies include Exagen (XGN), LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), and Accendra Health (ACH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does biote compare to Exagen?

biote (NASDAQ:BTMD) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

biote currently has a consensus price target of $2.50, suggesting a potential upside of 53.37%. Exagen has a consensus price target of $9.63, suggesting a potential upside of 27.99%. Given biote's higher possible upside, research analysts clearly believe biote is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

biote has a net margin of 3.19% compared to Exagen's net margin of -26.61%. biote's return on equity of -22.33% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Exagen	-26.61%	-104.46%	-28.93%

biote has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, Exagen has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

21.7% of biote shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

biote has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.30	$27.05M	$0.11	14.82
Exagen	$66.57M	2.74	-$19.95M	-$0.81	N/A

In the previous week, Exagen had 2 more articles in the media than biote. MarketBeat recorded 3 mentions for Exagen and 1 mentions for biote. biote's average media sentiment score of 1.89 beat Exagen's score of 1.08 indicating that biote is being referred to more favorably in the media.

Company	Overall Sentiment
biote	Very Positive
Exagen	Positive

Summary

biote beats Exagen on 10 of the 16 factors compared between the two stocks.

How does biote compare to LifeMD?

LifeMD (NASDAQ:LFMD) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

biote has lower revenue, but higher earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.81	$14.35M	-$0.05	N/A
biote	$192.22M	0.30	$27.05M	$0.11	14.82

biote has a net margin of 3.19% compared to LifeMD's net margin of 0.10%. biote's return on equity of -22.33% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
biote	3.19%	-22.33%	12.10%

LifeMD has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, biote has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

LifeMD currently has a consensus target price of $7.57, suggesting a potential upside of 132.25%. biote has a consensus target price of $2.50, suggesting a potential upside of 53.37%. Given LifeMD's stronger consensus rating and higher probable upside, research analysts clearly believe LifeMD is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 17.2% of LifeMD shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, LifeMD had 1 more articles in the media than biote. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for biote. biote's average media sentiment score of 1.89 beat LifeMD's score of 0.94 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeMD	Positive
biote	Very Positive

Summary

biote beats LifeMD on 9 of the 17 factors compared between the two stocks.

How does biote compare to Joint?

Joint (NASDAQ:JYNT) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

biote has higher revenue and earnings than Joint. biote is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.15
biote	$192.22M	0.30	$27.05M	$0.11	14.82

Joint has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, biote has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

biote has a consensus price target of $2.50, suggesting a potential upside of 53.37%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Joint has a net margin of 6.49% compared to biote's net margin of 3.19%. Joint's return on equity of 12.02% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
biote	3.19%	-22.33%	12.10%

76.9% of Joint shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Joint had 1 more articles in the media than biote. MarketBeat recorded 2 mentions for Joint and 1 mentions for biote. biote's average media sentiment score of 1.89 beat Joint's score of 0.93 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
Joint	Positive
biote	Very Positive

Summary

biote beats Joint on 10 of the 17 factors compared between the two stocks.

How does biote compare to Park Dental Partners?

biote (NASDAQ:BTMD) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, Park Dental Partners had 2 more articles in the media than biote. MarketBeat recorded 3 mentions for Park Dental Partners and 1 mentions for biote. biote's average media sentiment score of 1.89 beat Park Dental Partners' score of 1.74 indicating that biote is being referred to more favorably in the media.

Company	Overall Sentiment
biote	Very Positive
Park Dental Partners	Very Positive

biote presently has a consensus target price of $2.50, suggesting a potential upside of 53.37%. Park Dental Partners has a consensus target price of $28.50, suggesting a potential upside of 30.85%. Given biote's higher possible upside, equities analysts clearly believe biote is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

21.7% of biote shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 10.6% of Park Dental Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

biote has higher earnings, but lower revenue than Park Dental Partners. biote is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.30	$27.05M	$0.11	14.82
Park Dental Partners	$244.49M	0.42	-$360K	$1.05	20.74

biote has a net margin of 3.19% compared to Park Dental Partners' net margin of 0.00%. Park Dental Partners' return on equity of 0.00% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Park Dental Partners	N/A	N/A	N/A

Summary

biote beats Park Dental Partners on 7 of the 13 factors compared between the two stocks.

How does biote compare to Accendra Health?

Accendra Health (NYSE:ACH) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Accendra Health had 2 more articles in the media than biote. MarketBeat recorded 3 mentions for Accendra Health and 1 mentions for biote. biote's average media sentiment score of 1.89 beat Accendra Health's score of 1.16 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
Accendra Health	Positive
biote	Very Positive

biote has lower revenue, but higher earnings than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A
biote	$192.22M	0.30	$27.05M	$0.11	14.82

21.7% of biote shares are held by institutional investors. 2.3% of Accendra Health shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Accendra Health has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, biote has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Accendra Health presently has a consensus price target of $1.50, suggesting a potential upside of 23.46%. biote has a consensus price target of $2.50, suggesting a potential upside of 53.37%. Given biote's stronger consensus rating and higher possible upside, analysts clearly believe biote is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 3.19% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
biote	3.19%	-22.33%	12.10%

Summary

biote beats Accendra Health on 14 of the 17 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$55.69M	$10.05B	$7.31B	$12.78B
Dividend Yield	N/A	2.55%	2.53%	11.03%
P/E Ratio	14.82	29.48	210.50	22.08
Price / Sales	0.30	5.04	630.29	95.53
Price / Cash	2.67	126.73	79.17	53.57
Price / Book	-1.01	4.10	13.01	6.26
Net Income	$27.05M	$312.92M	$3.46B	$348.07M
7 Day Performance	10.14%	0.59%	1.95%	1.40%
1 Month Performance	-30.04%	1.13%	8.17%	4.59%
1 Year Performance	-51.49%	16.10%	26.28%	17.05%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	4.8442 of 5 stars	$1.63 +5.2%	$2.50 +53.4%	-53.2%	$55.69M	$192.22M	14.82	194	Positive News High Trading Volume
XGN Exagen	3.6466 of 5 stars	$7.60 -0.7%	$9.63 +26.6%	-22.5%	$184.15M	$66.57M	N/A	220	Positive News
LFMD LifeMD	3.5255 of 5 stars	$3.26 +3.8%	$7.57 +132.3%	-50.2%	$157.13M	$194.05M	N/A	230	Positive News
JYNT Joint	2.3027 of 5 stars	$8.45 +0.1%	N/A	-21.5%	$119.48M	$54.90M	31.30	320
PARK Park Dental Partners	4.3144 of 5 stars	$20.46 -1.4%	$28.50 +39.3%	N/A	$97.39M	$244.49M	19.49	1,212	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors